Resverlogix Corp. (RVXCF)
USD 0.03
(-2.79%)
USD 0.03
(-2.79%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | -12.74 Million USD | 20.18% |
| 2021 | -15.97 Million USD | 0.0% |
| 2019 | -22.95 Million USD | -126.8% |
| 2018 | 85.64 Million USD | 377.15% |
| 2017 | -30.9 Million USD | 9.5% |
| 2016 | -34.14 Million USD | -70.66% |
| 2015 | -20 Million USD | -136.55% |
| 2014 | -8.45 Million USD | 39.74% |
| 2013 | -14.03 Million USD | 59.47% |
| 2012 | -34.63 Million USD | -40.64% |
| 2011 | -24.62 Million USD | -12.65% |
| 2010 | -21.86 Million USD | 16.77% |
| 2009 | -26.26 Million USD | -58.24% |
| 2008 | -16.59 Million USD | 33.11% |
| 2007 | -24.81 Million USD | -57.91% |
| 2006 | -15.71 Million USD | -147.43% |
| 2005 | -6.35 Million USD | -121.23% |
| 2004 | -2.87 Million USD | -106.49% |
| 2003 | -1.39 Million USD | -171.11% |
| 2002 | -512.82 Thousand USD | -173.81% |
| 2001 | -187.29 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q3 | -1.1 Million USD | 23.81% |
| 2023 Q2 | -1.44 Million USD | 0.0% |
| 2022 Q4 | -2.51 Million USD | -13.03% |
| 2022 Q2 | -2.04 Million USD | 65.7% |
| 2022 FY | -12.74 Million USD | 20.18% |
| 2022 Q3 | -2.22 Million USD | -8.85% |
| 2022 Q1 | -5.96 Million USD | -5.62% |
| 2021 Q4 | -5.64 Million USD | -7.96% |
| 2021 Q1 | -1.64 Million USD | 0.0% |
| 2021 FY | -15.97 Million USD | 0.0% |
| 2021 Q2 | -3.45 Million USD | -109.78% |
| 2021 Q3 | -5.22 Million USD | -51.43% |
| 2020 Q3 | -3.25 Million USD | 21.68% |
| 2020 Q1 | -1.63 Million USD | 67.28% |
| 2020 Q2 | -4.16 Million USD | -154.81% |
| 2019 FY | -22.95 Million USD | -126.8% |
| 2019 Q4 | -4.99 Million USD | 85.94% |
| 2019 Q3 | -35.49 Million USD | -48.78% |
| 2019 Q2 | -23.85 Million USD | -154.05% |
| 2019 Q1 | 44.13 Million USD | 747.87% |
| 2018 Q3 | -10.9 Million USD | -133.55% |
| 2018 Q1 | -12.68 Million USD | 1.6% |
| 2018 Q2 | 32.51 Million USD | 356.28% |
| 2018 Q4 | -6.81 Million USD | 37.55% |
| 2018 FY | 85.64 Million USD | 377.15% |
| 2017 Q3 | -9.58 Million USD | -7.54% |
| 2017 FY | -30.9 Million USD | 9.5% |
| 2017 Q4 | -12.89 Million USD | -34.58% |
| 2017 Q1 | -9.76 Million USD | -1.12% |
| 2017 Q2 | -8.9 Million USD | 8.8% |
| 2016 FY | -34.14 Million USD | -70.66% |
| 2016 Q1 | -7.62 Million USD | -60.5% |
| 2016 Q3 | -7.59 Million USD | -6.82% |
| 2016 Q4 | -9.66 Million USD | -27.14% |
| 2016 Q2 | -7.11 Million USD | 6.66% |
| 2015 Q4 | -4.74 Million USD | -14.63% |
| 2015 Q3 | -4.14 Million USD | -18.57% |
| 2015 Q1 | -2.96 Million USD | -53.84% |
| 2015 Q2 | -3.49 Million USD | -17.92% |
| 2015 FY | -20 Million USD | -136.55% |
| 2014 FY | -8.45 Million USD | 39.74% |
| 2014 Q4 | -1.92 Million USD | -6.76% |
| 2014 Q3 | -1.8 Million USD | -2.15% |
| 2014 Q2 | -1.76 Million USD | 39.62% |
| 2014 Q1 | -2.92 Million USD | -56.75% |
| 2013 Q4 | -1.86 Million USD | 14.21% |
| 2013 Q1 | -9.4 Million USD | -12.7% |
| 2013 Q2 | -7.07 Million USD | 24.83% |
| 2013 Q3 | -2.17 Million USD | 69.24% |
| 2013 FY | -14.03 Million USD | 59.47% |
| 2012 Q1 | -6.87 Million USD | -25.37% |
| 2012 Q2 | -8.59 Million USD | -25.11% |
| 2012 FY | -34.63 Million USD | -40.64% |
| 2012 Q3 | -8.28 Million USD | 3.62% |
| 2012 Q4 | -8.34 Million USD | -0.69% |
| 2011 Q4 | -5.48 Million USD | 21.36% |
| 2011 Q1 | -6.76 Million USD | -39.3% |
| 2011 Q2 | -5.3 Million USD | 21.56% |
| 2011 Q3 | -6.97 Million USD | -31.4% |
| 2011 FY | -24.62 Million USD | -12.65% |
| 2010 Q2 | -5.45 Million USD | 2.21% |
| 2010 Q4 | -4.85 Million USD | 4.56% |
| 2010 FY | -21.86 Million USD | 16.77% |
| 2010 Q1 | -5.58 Million USD | 31.57% |
| 2010 Q3 | -5.08 Million USD | 6.78% |
| 2009 Q4 | -8.15 Million USD | -88.77% |
| 2009 FY | -26.26 Million USD | -58.24% |
| 2009 Q3 | -4.31 Million USD | 6.63% |
| 2009 Q2 | -4.62 Million USD | -22.49% |
| 2009 Q1 | -3.77 Million USD | 23.08% |
| 2008 FY | -16.59 Million USD | 33.11% |
| 2008 Q2 | -4.2 Million USD | 41.88% |
| 2008 Q3 | -4.71 Million USD | -12.32% |
| 2008 Q4 | -4.91 Million USD | -4.05% |
| 2008 Q1 | -7.22 Million USD | -31.85% |
| 2007 FY | -24.81 Million USD | -57.91% |
| 2007 Q3 | -6.68 Million USD | -22.89% |
| 2007 Q2 | -5.44 Million USD | 30.26% |
| 2007 Q1 | -7.8 Million USD | -109.95% |
| 2007 Q4 | -5.48 Million USD | 18.0% |
| 2006 Q1 | -2.04 Million USD | -59.76% |
| 2006 FY | -15.71 Million USD | -147.43% |
| 2006 Q2 | -1.75 Million USD | 14.18% |
| 2006 Q3 | -2.82 Million USD | -60.52% |
| 2006 Q4 | -3.71 Million USD | -31.75% |
| 2005 Q3 | -1.77 Million USD | -59.71% |
| 2005 FY | -6.35 Million USD | -121.23% |
| 2005 Q2 | -1.11 Million USD | -16.94% |
| 2005 Q1 | -950.08 Thousand USD | -3.49% |
| 2005 Q4 | -1.28 Million USD | 27.77% |
| 2004 Q1 | -709.28 Thousand USD | -204.51% |
| 2004 FY | -2.87 Million USD | -106.49% |
| 2004 Q2 | -440.22 Thousand USD | 37.93% |
| 2004 Q3 | -293.55 Thousand USD | 33.32% |
| 2004 Q4 | -918.04 Thousand USD | -212.74% |
| 2003 Q1 | -248.24 Thousand USD | -161.06% |
| 2003 Q3 | -146.28 Thousand USD | 48.73% |
| 2003 Q4 | -232.92 Thousand USD | -59.23% |
| 2003 Q2 | -285.33 Thousand USD | -14.94% |
| 2003 FY | -1.39 Million USD | -171.11% |
| 2002 Q3 | -12.95 Thousand USD | 49.44% |
| 2002 Q4 | -95.09 Thousand USD | -634.03% |
| 2002 Q2 | -25.62 Thousand USD | -436.37% |
| 2002 Q1 | -4777.27 USD | 0.0% |
| 2002 FY | -512.82 Thousand USD | -173.81% |
| 2001 FY | -187.29 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -854.673% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -152.732% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 28.565% |
| Nascent Biotech, Inc. | -2.22 Million USD | -471.735% |
| Rebus Holdings, Inc. | -664 Thousand USD | -1820.03% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 115.576% |
| Qrons Inc. | -643.67 Thousand USD | -1880.652% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -3172.583% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 77.032% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -2968.506% |
| Skye Bioscience, Inc. | -13.67 Million USD | 6.75% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 82.24% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 359.4% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -4771.125% |
| SQZ Biotechnologies Company | -75.82 Million USD | 83.186% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -347.254% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -729.987% |
| Mesoblast Limited | -84.14 Million USD | 84.849% |
| Marizyme, Inc. | -34.08 Million USD | 62.598% |
| Genus plc | 6.4 Million USD | 299.203% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 230.86% |
| Pharming Group N.V. | -4.87 Million USD | -161.274% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -541.789% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -1268.829% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -52.683% |
| ContraFect Corporation | -56.88 Million USD | 77.59% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -179.907% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -809.35% |
| IMV Inc. | -38.67 Million USD | 67.033% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -363.459% |
| MultiCell Technologies, Inc. | -722.81 USD | -1763710.683% |
| ONE Bio Corp. | 13.68 Million USD | 193.184% |
| Accustem Sciences Inc. | -3.74 Million USD | -240.298% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 78.388% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -2539.206% |
| Q BioMed Inc. | -3.44 Million USD | -270.006% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 460.141% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -385.21% |
| Biomind Labs Inc. | -1 Million USD | -1162.774% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 76.808% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -339.431% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -91.772% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -583.823% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -42464.77% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 19.665% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -559.678% |
| GB Sciences, Inc. | -1.42 Million USD | -797.495% |
| Alpha Cognition Inc. | -9.7 Million USD | -31.357% |
| HST Global, Inc. | -140.9 Thousand USD | -8947.812% |
| CSL Limited | 3.7 Billion USD | 100.344% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -1033.339% |
| Halberd Corporation | -75.05 Thousand USD | -16887.342% |
| Enzolytics Inc. | -2.14 Million USD | -493.308% |
| Agentix Corp. | -1.37 Million USD | -829.393% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -302.396% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 97.001% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -1121.169% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -336.693% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -707.228% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -274.422% |
| AVAX Technologies, Inc. | 6.69 Million USD | 290.486% |
| Zenith Capital Corp. | -8.94 Million USD | -42.558% |
| Genscript Biotech Corporation | -415.79 Million USD | 96.934% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -73081.792% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -419.24% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -7333.406% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -535.937% |
| Kadimastem Ltd | -3.04 Million USD | -319.341% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -1195.56% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -915.048% |
| BioStem Technologies, Inc. | -7.77 Million USD | -63.891% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -6924.823% |
| LadRx Corporation | -3.82 Million USD | -233.427% |
| Cell Source, Inc. | -4.32 Million USD | -194.751% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -1755.885% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -1755.885% |
| NovAccess Global Inc. | -2.46 Million USD | -416.832% |
| Affymax, Inc. | -15.04 Million USD | 15.267% |
| Itoco Inc. | -919.14 Thousand USD | -1287.057% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -200.796% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -1039.321% |
| Mobile Lads Corp. | -554.55 Thousand USD | -2198.981% |
| CytoDyn Inc. | -18.05 Million USD | 29.4% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -50551.569% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -5692.946% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -2157.567% |
| SYBLEU INC | -149.18 Thousand USD | -8446.052% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -601.914% |
| International Stem Cell Corporation | -663 Thousand USD | -1822.926% |
| Bioxytran, Inc. | -3.82 Million USD | -233.731% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -24119.225% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -62579.449% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 64.846% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -687.948% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -1632.59% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -309.804% |
| Neutra Corp. | -229.48 Thousand USD | -5455.459% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 27.311% |
| PureTech Health plc | -146.19 Million USD | 91.28% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 40.678% |
| IXICO plc | -1.43 Million USD | -787.196% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -34.327% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 89.533% |
| CSL Limited | 3.81 Billion USD | 100.334% |
| Cellectis S.A. | -108.85 Million USD | 88.288% |